Conventional dual antiplatelet therapy (DAPT) for patients with acute coronary syndromes
undergoing percutaneous coronary intervention comprises aspirin with a potent P2Y …

Background: Early outcomes of patients in the PRAGUE-18 (Comparison of Prasugrel and
Ticagrelor in the Treatment of Acute Myocardial Infarction) study did not find any significant …

Globally, much morbidity and premature mortality arises from coronary artery disease (CAD).
Coronary artery atherothrombosis is the dominant cause of acute coronary syndromes …

Thrombo-inflammation describes the complex interplay between blood coagulation and
inflammation that plays a critical role in cardiovascular diseases. The third Maastricht …

Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel
and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment …

Delayed onset of action of oral P2Y 12 inhibitors in ST-elevation myocardial infarction
(STEMI) patients may increase the risk of acute stent thrombosis. Available parenteral anti …

Study Objective To compare the effectiveness and safety of ticagrelor versus prasugrel in
preventing recurrent cardiovascular disease (CVD) and major bleeding events in patients …

Background Clopidogrel, prasugrel and ticagrelor, acting on platelet P2Y12 receptor, are
commonly used for prevention of stent thrombosis (ST) among patients who underwent …

Background and aims We aimed to compare the effectiveness of ticagrelor vs. clopidogrel or
prasugrel on recurrence of acute coronary syndromes (ACS) in real-life conditions, as …

Pharmacodynamic data and large phase III clinical trials have clearly established ticagrelor
and prasugrel as first-line therapies in acute coronary syndrome (ACS) in preference to …